About UCSF Search UCSF UCSF Medical Center

Nicholas A. Butowski, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
butowski_nicholas

Assistant Professor, Department of Neurological Surgery, and Director, Neuro-Oncology Clinical Services, UCSF

Phone: (415) 353-7500 (appts)
Box 0372, UCSF
San Francisco, CA 94143-0372

View on UCSF Profiles


Additional Websites


Education

Northwestern University, Evanston, IL, BA, 1991-1995, Philosophy/Religion
University of Illinois at Chicago, Chicago, IL, MD, 1995-1999
Evanston-Northwestern Hospital, Evanston, IL, Intern, 1999-2000, Medicine
University of California, San Francisco, San Francisco, CA, Fellow, 2003-2005, Neuro-Oncology

Professional Experience

  • 2000-2003
    Residency in Neurology; Department of Neurology, University of California, San Francisco, CA
  • 2003-2004
    Fellow, University of California, San Francisco, Department of Neurological Surgery, Neuro-Oncology Service
  • 2004-2005
    Clinical Instructor, University of California, San Francisco, Department of Neurological Surgery, Neuro-Oncology Service
  • 2005-present
    Assistant Clinical Professor, University of California, San Francisco, Department of Neurological Surgery, Neuro-Oncology Service
  • 2006-present
    Director of Clinical Services, Dept. of Neurological Surgery, Neuro-Oncology Service, Brain Tumor Research Center, University of California, San Francisco (UCSF)
  • 2005-present
    Assoc Member of the Brain Tumor Research Center, Dept. of Neurological Surgery, UCSF
  • 2005-present
    Assoc Member of the Comprehensive Cancer Center, UCSF
  • 2009-present
    Co-chair, CNS Cancer Program Site Committee
  • 2009-present
    Member, UCSF Cancer Program Protocol Review Committee
  • 2009-present
    Member, National Comprehensive Cancer Center Network CNS Cancer Guideline Committee

Selected Publications

  1. Han SJ, Rutledge WC, Molinaro A, Chang S, Clarke JL, Prados M, Berger MS, Butowski N. Journal of neuro-oncology award 105 the effect of timing of radiotherapy in patients with newly-diagnosed glioblastoma multiforme receiving temozolomide: an analysis based on the university of california, san francisco experience. Neurosurgery. 2014 Aug; 61 Suppl 1:193.
    View on PubMed
  2. Lacouture ME, Elizabeth Davis M, Elzinga G, Butowski N, Tran D, Villano JL, Dimeglio L, Davies AM, Wong ET. Characterization and Management of Dermatologic Adverse Events With the NovoTTF-100A System, a Novel Anti-mitotic Electric Field Device for the Treatment of Recurrent Glioblastoma. Semin Oncol. 2014 Jun; 41 Suppl 4:S1-S14.
    View on PubMed
  3. Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, Butowski NA, Chang SM, Clarke JL, McDermott MW, Prados MD, Sloan AE, Bruce JN, Parsa AT. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol. 2014 Jan; 16(2):274-9.
    View on PubMed
  4. Butowski N, Wong ET, Mehta MP, Wilson LK. A Roundtable Discussion on the Clinical Challenges and Options for the Treatment of Glioblastoma: Introducing a Novel Modality, TTFields. Semin Oncol. 2013 Dec; 40(6):S2-4.
    View on PubMed
  5. Nabors LB, Ammirati M, Bierman PJ, Brem H, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Maor MH, Moots PL, Morrison T, Mrugala MM, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK, Tran D, Tran N, Vrionis FD, Wen PY, McMillian N, Ho M. Central nervous system cancers. J Natl Compr Canc Netw. 2013 Sep 1; 11(9):1114-51.
    View on PubMed
  6. Bloch O, Safaee M, Sun MZ, Butowski NA, McDermott MW, Berger MS, Aghi MK, Parsa AT. Disseminated progression of glioblastoma after treatment with bevacizumab. Clin Neurol Neurosurg. 2013 Sep; 115(9):1795-801.
    View on PubMed
  7. Lupo JM, Essock-Burns E, Molinaro AM, Cha S, Chang SM, Butowski N, Nelson SJ. Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme. Neuro Oncol. 2013 Apr; 15(4):480-9.
    View on PubMed
  8. Chen PY, Ozawa T, Drummond DC, Kalra A, Fitzgerald JB, Kirpotin DB, Wei KC, Butowski N, Prados MD, Berger MS, Forsayeth JR, Bankiewicz K, James CD. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro Oncol. 2013 Feb; 15(2):189-97.
    View on PubMed
  9. Butowski N, Chang SM. Endpoints for clinical trials and revised assessment in neuro-oncology. Curr Opin Neurol. 2012 Dec; 25(6):780-5.
    View on PubMed
  10. Crane CA, Han SJ, Ahn B, Oehlke J, Kivett V, Fedoroff A, Butowski N, Chang SM, Clarke J, Berger MS, McDermott MW, Prados MD, Parsa AT. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res. 2013 Jan 1; 19(1):205-14.
    View on PubMed
  11. Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezhnikov A, Lunceford J, Chen C, Giannotti M, Hing J, Beckman R, Lorusso P. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol. 2012 Jul 1; 30(19):2307-13.
    View on PubMed
  12. Clark AJ, Lamborn KR, Butowski NA, Chang SM, Prados MD, Clarke JL, McDermott MW, Parsa AT, Berger MS, Aghi MK. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery. 2012 Feb; 70(2):361-70.
    View on PubMed
  13. Butowski NA, Chang SM. General and neurological complications of targeted therapy. Handb Clin Neurol. 2012; 105:937-45.
    View on PubMed
  14. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2011 Nov 1; 29(31):4175-80.
    View on PubMed
  15. Butowski N, Chang SM, Lamborn KR, Polley MY, Pieper R, Costello JF, Vandenberg S, Parvataneni R, Nicole A, Sneed PK, Clarke J, Hsieh E, Costa BM, Reis RM, Hristova-Kazmierski M, Nicol SJ, Thornton DE, Prados MD. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 2011 Dec; 13(12):1331-8.
    View on PubMed
  16. Butowski N. Anti-angiogenic therapy in glioma. Clin Transl Oncol. 2011 May; 13(5):294-300.
    View on PubMed
  17. Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Junck L, Linette GP, Loeffler JS, Maor MH, Michael M, Moots PL, Morrison T, Mrugala M, Nabors LB, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK, Vrionis FD, Wen PY. Central nervous system cancers. J Natl Compr Canc Netw. 2011 Apr; 9(4):352-400.
    View on PubMed
  18. Parvataneni R, Polley MY, Freeman T, Lamborn K, Prados M, Butowski N, Liu R, Clarke J, Page M, Rabbitt J, Fedoroff A, Clow E, Hsieh E, Kivett V, Deboer R, Chang S. Identifying the needs of brain tumor patients and their caregivers. J Neurooncol. 2011 Sep; 104(3):737-44.
    View on PubMed
  19. Butowski N. Medical management of brain metastases. Neurosurg Clin N Am. 2011 Jan; 22(1):27-36, v-vi.
    View on PubMed
  20. Clark AJ, Butowski NA, Chang SM, Prados MD, Clarke J, Polley MY, Sughrue ME, McDermott MW, Parsa AT, Berger MS, Aghi MK. Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg. 2011 Jun; 114(6):1609-16.
    View on PubMed

Go to UCSF Profiles, powered by CTSI